Randomized Trialhigh evidence
Survodutide Once Weekly for the Treatment of Adults with Obesity.
The New England journal of medicine·June 7, 2026·PMID 42253238
Why it mattersSurvodutide offers a new dual-agonist mechanism that may provide robust weight loss, expanding the therapeutic toolkit for obesity management beyond current GLP-1 receptor agonists.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled